PROMETEUS Kick-Off Meeting - February 18-19, 2019

February 20, 2019

CALIXAR, the French biotech company specialized in the native isolation of membrane therapeutic targets and antigens, is proud to announce the official launch of the Protein and Membrane Technology Consortium (Prometeus). This project has received funding from the European Union’s H2020-MSCA-RISE-2018.

Coordinated by Prof. Beatrice VALLONE from the University of Rome, the aim of the Prometeus Consortium is to provide high-quality multidisciplinary knowledge through training and research on membrane protein and protein complexes as molecular tools for drug development and theranostics. The focus of the action is the creation of a synergistic pipeline to yield target membrane protein structure-function characterization and bioactive molecule design, harnessing the complementary skills from Academic and SME participants.

The role of CALIXAR within this consortium will be to bring its unique approach and recognized expertise in native membrane proteins solubilization and stabilization to enable drug discovery.

More information about Prometeus Consortium

Share this post

Secure and boost
your discovery programs

Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.